Vertex Pharma (VRTX) Announces EC Approval for KAFTRIO in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. SPY
2. USO
3. META
4. MSFT
5. MU
6. COST
7. IONS
8. CME
9. AVAV
10. SKHY

Go back to Vertex Pharma (VRTX) Announces EC Approval for KAFTRIO in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older

Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508

April 28, 2021 7:30 AM EDT

- New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type -

- People with gating (F/G) or residual function (F/RF) mutations now eligible for the triple combination therapy -

LONDON--(BUSINESS WIRE)--... More